Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. - Wikidata - wikimedia - TriplyDB

Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.

Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.

http://www.wikidata.org/entity/Q40974954

about

Macrophage-inducing FasL on chondrocytes forms immune privilege in cartilage tissue engineering, enhancing in vivo regeneration Receptor-interacting protein shuttles between cell death and survival signaling pathways Anoikis mediators in oral squamous cell carcinoma.Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma.The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells.Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2.IFN-gammaupregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma.Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression.

P2860

Q28306234-0E6053B8-FCB2-4F94-86B7-E087D6F38E00 Q33623823-B9B6980C-4D93-47DC-9695-D71D28BB61BD Q34770470-77F33B95-D730-42A4-8E85-C0C278212094 Q36622253-2A2A608F-6303-42C9-9E24-8F06CEC8B530 Q38296608-AB2EAB6C-6E13-4655-9E51-24564800D8FE Q40623138-76AD6DDC-AF7E-47AF-9BF3-DCA636CA6370 Q43853017-1AE3A75E-2F40-4D9C-8854-6FC6D7CCAB00 Q44062524-BCD468BB-21D5-4A67-A6B1-E47A6DC17C88 Q54028713-C1F3CF78-53E6-4DF9-8D95-89810A859B6A

P2860

Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.

http://www.wikidata.org/entity/Q40974954

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Regulation of CD95 (Apo-1/Fas) ...... nterferon-gamma and cisplatin.

@en

type

label

Regulation of CD95 (Apo-1/Fas) ...... nterferon-gamma and cisplatin.

@en

prefLabel

Regulation of CD95 (Apo-1/Fas) ...... nterferon-gamma and cisplatin.

@en

P1433

Q40974954-618A0982-350A-40F8-9EDE-930751F35870

P1476

Q40974954-A4423746-02A1-4882-9793-094723A367D5

P2093

Q40974954-0EFDB0B1-81A0-4918-9C76-9A741A6A74D2

Q40974954-58BA1E03-961C-4BC3-8FF3-AC7203A6C9CD

Q40974954-5909B8D4-2C0E-4516-B184-B34E15C3B686

Q40974954-66080750-8438-4BFE-8874-6AD210EEC6BD

Q40974954-88535339-9EB0-4F7A-8DD6-64A4372FB97E

Q40974954-9762BB93-5273-4E18-BEBF-E5CD42C311CD

Q40974954-9DA7E9EA-298F-471D-8241-29894F1A2DE7

P2860

Q40974954-0683785E-ECC0-47E9-814F-5F9518DCE640

Q40974954-35FF7D7F-5E76-426F-A489-F7F8702E7CD0

Q40974954-4BBF1C8C-16F0-490F-8F37-216C52CF54A4

Q40974954-504C9C13-684C-4F1C-936C-9EB067E32431

Q40974954-633BCBB4-B443-4BC4-9ADA-4795FFF0116F

Q40974954-6A05DF7D-068C-42EB-92E6-0E0E33B0B2BA

Q40974954-836CA5CF-5325-4DF6-B9C4-3F0D60187867

Q40974954-958E4B08-EC25-4AF6-839C-CA7C66315F4B

Q40974954-9F27F400-44F8-4307-B93D-9B5A0F195964

Q40974954-AAA2BC6B-94B5-4993-9EAF-29E6B6CE5400

P304

Q40974954-A7AEBC56-221F-49F1-AD0E-EA2C79A81A79

P31

Q40974954-BC7D2ED7-9F2F-40C9-AE6F-826EFE45DB3D

P356

Q40974954-6B30AFF1-2F68-4A6F-95C2-B5669C7258F5

P433

Q40974954-A523DC4F-BFFD-4AFF-8924-833EA93F9242

P478

Q40974954-98FBD275-682E-49E3-85F8-7DFC5E310D61

P50

Q40974954-8C5375B0-B4BB-46A9-9414-DB8DC6EBCFCE

Q40974954-D494764E-3B8D-495D-A247-0EA9A82DABB6

P577

Q40974954-F2724DB6-70DD-4F22-87A6-C53E78CE3CD2

P698

Q40974954-09AC9B7E-A770-43AD-A58C-47A234214787

P356

(SICI)1097-0215(19990209)80:4%3C564::AID-IJC14%3E3.0.CO;2-X

P1433

International Journal of Cancer

P1476

Regulation of CD95 (Apo-1/Fas) ...... nterferon-gamma and cisplatin.

@en

P2093

C Moers

http://www.w3.org/2001/XMLSchema#string

D Häussinger

http://www.w3.org/2001/XMLSchema#string

D Niederacher

http://www.w3.org/2001/XMLSchema#string

J Even

http://www.w3.org/2001/XMLSchema#string

M Müschen

http://www.w3.org/2001/XMLSchema#string

U Koldovsky

http://www.w3.org/2001/XMLSchema#string

U Warskulat

http://www.w3.org/2001/XMLSchema#string

P2860

A naturally occurring soluble isoform of murine Fas generated by alternative splicing

Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide

Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L).

Quantitative titration of nucleic acids by enzymatic amplification reactions run to saturation.

Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines.

Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.

Immunohistochemical detection of Fas antigen in oral epithelia.

Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury.

Deranged CD95 system in a case of Churg-Strauss vasculitis.

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

P304

564-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/(SICI)1097-0215(19990209)80:4<564::AID-IJC14>3.0.CO;2-X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Matthias W. Beckmann

P577

1999-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9935158

http://www.w3.org/2001/XMLSchema#string